Extensive studies have revealed that EZH2 is overexpressed in various malignancies7–11 and acquires gain-of-function mutations in subtypes of lymphomas12–14, highlighting an oncogenic role for EZH2 in cancer progression. Here, EZH2 is linked to cancer.